Charles Hughes, MD
Colon & Rectal Surgery · Scranton, PANPI 1902807282
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 24.4% of the total.
Across 289 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$657
- AbbVie$551
- Takeda Pharmaceuticals U.S.A., Inc.$355
- Daiichi Sankyo Inc.$257
- QOL Medical, LLC$196
- plus $1K from 17 others
Across 7 payments — averaging $3037.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bolton Medical Inc$21K
What the payments were for
- Food & beverage$4,32498%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 72 | $1,078 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $657 |
| AbbVie | 35 | $551 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $355 |
| Daiichi Sankyo Inc. | 19 | $257 |
| QOL Medical, LLC | 12 | $196 |
| Lilly USA, LLC | 11 | $187 |
| Nestle Healthcare Nutrition Inc. | 9 | $167 |
| Gilead | 13 | $159 |
| Regeneron Healthcare Solutions, Inc. | 9 | $157 |
| Merck | 8 | $127 |
| Aimmune Therapeutics, Inc. | 6 | $110 |
| Ardelyx, Inc. | 5 | $102 |
| Phathom Pharmaceuticals, Inc. | 6 | $69 |
| Ferring Pharmaceuticals Inc. | 3 | $63 |
| Intercept Pharmaceuticals, Inc. | 3 | $58 |
| Redhill Biopharma Inc. | 2 | $31 |
| Bristol Myers Squibb | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Axonics, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Pfizer | 1 | $11 |
How this compares
$4,408 in reported general payments places this provider in the 65th percentile of 108 colon & rectal surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 13 | $92 |
| Tramadol Hcl | 25 | $48 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Scranton
- Bogdan ProtyniakWilkes-Barre$429K
- John MarksWynnewood$155K
- Joshua BleierPhiladelphia$86K
- Richard FortunatoPittsburgh$80K
- Najjia MahmoudPhiladelphia$63K
- James McCormickMonroeville$55K
- Juan PoggioPhiladelphia$49K
- Christopher BuzasDanville$25K
- David ZebleyAbington$24K
- Jennifer Holder-MurrayPittsburgh$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.